TG Therapeutics (TGTX)
(Delayed Data from NSDQ)
$16.19 USD
-0.23 (-1.40%)
Updated May 3, 2024 04:00 PM ET
After-Market: $16.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Brokerage Reports
TG Therapeutics, Inc. [TGTX]
Reports for Purchase
Showing records 181 - 200 ( 275 total )
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Glance at ASCO Update as Phase III Moves Along; Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
1Q15 Update-Signs of GENUINE Progress in Clinical Development
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: TG Therapeutics, Inc.
Industry: Medical - Products
1Q15 Results; Expect Additional Stock Upside with 2015 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
2015 AACR Meeting Highlights-Cancer Gets a Dose of Brotherly Love
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
IRAK4 Program Gaining Momentum; Could Also Expand to Immune Setting
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Healthcare: Shaky Sector; Focus on Defined Catalysts for Remainder of 2015
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Healthcare Recap: Opportunities and Catalyst Focus Name of Game Going Forward
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
FY2014 Results; Data and Pivotal Studies in 2015; Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
4Q14 Update-Pipeline of Enviable Assets Marches to Registrational Studies
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Building a Pipeline of Enviable Assets-TG Licenses Checkpoint Inhibitors
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Checking-In the Checkpoint Inhibitors Playing Field
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
ASH Highlights from Days 3-4 - Seeking the Right Combinations and Doses
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Oh What an ASH; Now What? Target Upped to $33; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.